Kezar Life Sciences (KZR) Stock Forecast, Price & News

Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

Is Kezar Life Sciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kezar Life Sciences stock.
View analyst ratings for Kezar Life Sciences or view top-rated stocks.

Are investors shorting Kezar Life Sciences?

Kezar Life Sciences saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 3,600,000 shares, a decline of 14.7% from the April 30th total of 4,220,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is presently 3.5 days.
View Kezar Life Sciences' Short Interest.

When is Kezar Life Sciences' next earnings date?

Kezar Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Kezar Life Sciences.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) posted its quarterly earnings results on Thursday, May, 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02.
View Kezar Life Sciences' earnings history.

What price target have analysts set for KZR?

3 equities research analysts have issued 1 year target prices for Kezar Life Sciences' shares. Their forecasts range from $14.00 to $22.00. On average, they expect Kezar Life Sciences' share price to reach $16.67 in the next year. This suggests a possible upside of 218.1% from the stock's current price.
View analysts' price targets for Kezar Life Sciences or view top-rated stocks among Wall Street analysts.

Who are Kezar Life Sciences' key executives?

Kezar Life Sciences' management team includes the following people:

• Mr. John Franklin Fowler, Co-Founder, CEO & Director (Age 49, Pay $905.06k)
• Dr. Christopher J. Kirk Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 49, Pay $658.81k)
• Dr. Noreen Roth Henig M.D., Chief Medical Officer (Age 57, Pay $705.53k)
• Dr. Jack Taunton Ph.D., Co-Founder
• Mr. Marc L. Belsky, CFO & Sec. (Age 67)
• Mr. Michael Wolfe, VP of Fin. & Bus. Operations
• Ms. Gitanjali Jain, VP of Investor Relations & External Affairs
• Mr. Mark Schiller, Sr. VP of Legal Affairs
• Dr. Neel K. Anand Ph.D., VP of Medicinal Chemistry & Head of Drug Discovery
• Ms. Pattie Chiang, VP & Corp. Controller

Who are some of Kezar Life Sciences' key competitors?

Some companies that are related to Kezar Life Sciences include Celularity (CELU), BELLUS Health (BLUSF), Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), MannKind (MNKD), Prometheus Biosciences (RXDX), NGM Biopharmaceuticals (NGM), Agios Pharmaceuticals (AGIO), Arcutis Biotherapeutics (ARQT), Reata Pharmaceuticals (RETA), Innoviva (INVA), Vectura Group (VEGPF), BridgeBio Pharma (BBIO), Cassava Sciences (SAVA) and Lyell Immunopharma (LYEL).
View all of KZR's competitors.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL).

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (8.23%), BlackRock Inc. (5.11%), State Street Corp (3.95%), Vanguard Group Inc. (3.93%), Victory Capital Management Inc. (3.09%) and Northern Trust Corp (0.77%). Company insiders that own Kezar Life Sciences stock include Equal Talent Investments Ltd, Franklin M Berger and Michael Kauffman.
View institutional ownership trends for Kezar Life Sciences.

Which institutional investors are selling Kezar Life Sciences stock?

KZR stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Bellevue Group AG, Invesco Ltd., Prosight Management LP, Renaissance Technologies LLC, EAM Investors LLC, Citigroup Inc., and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Kezar Life Sciences or view top insider-selling stocks.

Which institutional investors are buying Kezar Life Sciences stock?

KZR stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., State Street Corp, Vanguard Group Inc., BlackRock Inc., Goldman Sachs Group Inc., Slow Capital Inc., Ghost Tree Capital LLC, and Simplex Trading LLC. Company insiders that have bought Kezar Life Sciences stock in the last two years include Equal Talent Investments Ltd, and Franklin M Berger.
View insider buying and selling activity for Kezar Life Sciences or or view top insider-buying stocks.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $5.24.

How much money does Kezar Life Sciences make?

Kezar Life Sciences has a market capitalization of $316.58 million. The company earns $-54.63 million in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Kezar Life Sciences have?

Kezar Life Sciences employs 56 workers across the globe.

What is Kezar Life Sciences' official website?

The official website for Kezar Life Sciences is www.kezarlifesciences.com.

How can I contact Kezar Life Sciences?

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (650) 822-5600 or via email at [email protected].